20
Participants
Start Date
February 7, 2020
Primary Completion Date
February 25, 2022
Study Completion Date
October 20, 2022
Tocilizumab 162Mg/0.9Ml Autoinjector
Patients will receive high-dose pulse intravenous methylprednisolone (500 mg ) for 3 consecutive days (Day 0-1-2) and subsequently will be treated weekly with Tocilizumab 162 mg s.c. for 52-weeks and then following according to SOC
Ausl-Irccs - S.C. Di Reumatologia, Reggio Emilia
Azienda USL Reggio Emilia - IRCCS
OTHER_GOV